The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities

2011 ◽  
Vol 32 (2) ◽  
pp. 85-90 ◽  
Author(s):  
Vasiliki Filippi ◽  
Joulia Malamitsi ◽  
Fani Vlachou ◽  
Fotios Laspas ◽  
Evangelos Georgiou ◽  
...  
2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 123-123
Author(s):  
Gary Schnur ◽  
Katherine Glass ◽  
Chad W Cummings ◽  
Alberto J. Montero ◽  
Jame Abraham ◽  
...  

123 Background: The Cleveland Clinic is utilizing disease specific teams to craft care paths for value based disease management. The report by Groheux (JNCI 2012; 104:1879-1887), reported 18 FDG-PET-CT detected distant metastasis in 10.7, 17.5 and 36.5% of stage IIB- IIIB breast cancer patients. Based on this report, the breast team incorporated 18 FDG-PET- CT imaging for initial staging of IIB-IIIB patients. Methods: Treatment algorithms were developed by a multi-disciplinary breast cancer team. The content was reviewed by stakeholders throughout the health system, and feedback was incorporated into the care paths as appropriate. Content was communicated using physician meetings, electronic communication, tumor boards, and operational pilots. The treatment algorithm, along with the supporting narrative, was placed on the cancer center intranet, accessible to all practicing physicians. Additional intranet analysis was performed using Google Analytics, which identifies the site location and frequency of document downloads. We retrospectively examined the impact of this posting after one year (7/2014-7/2015). Manual chart review identified new patient consults for Stage IIB-IIIB breast cancer at our main campus and highest volume regional sites. Results: PET scans were ordered in 36 stage IIB, 19 stage IIIA, and 3 stage IIIB patients. Of the 36 IIB patients scanned, occult metastatic disease was noted in 1, and 2 patients migrated to IIIA without a change in treatment. 19 IIIA patients had no change in stage, although an asymptomatic second primary lung cancer was discovered in 1 .Three stage IIIB patients were without staging change. Conclusions: PET/CT imaging did not contribute to patient management for stage IIB-IIIB breast cancer patients at our institution, unlike the results reported elsewhere. Analysis of care path metrics allows us to expediently review and adjust recommendations to affiliated physicians.


2012 ◽  
Vol 15 (4) ◽  
pp. 441 ◽  
Author(s):  
Young Jin Choi ◽  
Young Duck Shin ◽  
Yoon Hee Kang ◽  
Moon Soo Lee ◽  
Min Koo Lee ◽  
...  

2012 ◽  
Vol 39 (5) ◽  
pp. 852-863 ◽  
Author(s):  
C. Riegger ◽  
J. Herrmann ◽  
J. Nagarajah ◽  
J. Hecktor ◽  
S. Kuemmel ◽  
...  

2006 ◽  
Vol 33 (7) ◽  
pp. 785-791 ◽  
Author(s):  
C. Rousseau ◽  
E. Bourbouloux ◽  
L. Campion ◽  
N. Fleury ◽  
B. Bridji ◽  
...  

2009 ◽  
Vol 12 (3) ◽  
pp. 163
Author(s):  
Yong Hun Kim ◽  
Jin Sun Lee ◽  
Chul Joo Lee ◽  
Je Ryong Kim ◽  
Eil Sung Chang

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
In Hee Lee ◽  
Soo Jung Lee ◽  
Jeeyeon Lee ◽  
Jin Hyang Jung ◽  
Ho Yong Park ◽  
...  

Abstract Background Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative breast cancer, the response to NAC is variable and mostly limited. This study was an investigation of the predictive relevance of parameters of 18F-FDG PET/CT for the pCR to NAC in patients with HR-positive, HER2–negative breast cancer. Methods: AH total of 109 consecutive HR-positive and HER2-negative breast cancer patients who were treated with NAC were enrolled in this prospective cohort study. The relationships between pretreatment 18F-FDG PET/CT and clinical outcomes including pathologic response to NAC were evaluated. Results: All patients finished their planned NAC cycles and eight patients (7.3%) achieved pCR. In the receiver operating characteristic (ROC) curve analysis, pSUVmax exhibited high sensitivity and specificity for predicting pCR. Furthermore, multivariate logistic regression analysis revealed pSUVmax as a predictive factor for pCR (hazard ratio = 17.452; 95% CI = 1.847–164.892; p = 0.013). Conclusion The results of this study suggest that 18F-FDG PET/CT pSUVmax is a predictive factor for pCR of HR-positive, HER2-negative breast cancer to NAC.


2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Daniëlle Koopman ◽  
Jorn A. van Dalen ◽  
Hester Arkies ◽  
Ad H. J. Oostdijk ◽  
Anne Brecht Francken ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document